Comparative evaluation of disodium edetate and diethylenetriaminepentaacetic acid as iron chelators to prevent metal-catalyzed destabilization of a therapeutic monoclonal antibody

Journal of Pharmaceutical Sciences

Volumn 99, Issue 10, 2010, Pages 4239-4250

  Zhou, Shuxia ^a   Zhang, Bo ^a   Sturm, Emily ^b   Teagarden, Dirk L ^a   Schöneich, Christian ^c   Kolhe, Parag ^a   Lewis, Lavinia M ^a   Muralidhara, Bilikallahalli K ^a   Singh, Satish K ^a  

^a PFIZER INC   (United States)

^b PURDUE UNIVERSITY   (United States)

^c UNIVERSITY OF KANSAS   (United States)

Author keywords

Binding; Chelator; Deamidation; Fragmentation; Monoclonal antibody; Oxidation; Protein aggregation; Protein formulation; Protein structure; Stability

Indexed keywords

EDETATE DISODIUM; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G2; IMMUNOGLOBULIN G2 MONOCLONAL ANTIBODY; IRON; IRON CHELATE; MONOCLONAL ANTIBODY; PENTETIC ACID; UNCLASSIFIED DRUG;

ARTICLE; CATALYSIS; CATALYST; DEAMINATION; DRUG STABILITY; EVALUATION; OXIDATION; PROTEIN AGGREGATION; PROTEIN TERTIARY STRUCTURE; REACTION ANALYSIS; STOICHIOMETRY; THERMODYNAMICS;

EID: 77957338970     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.22141     Document Type: Article

References (52)

1. Eisenstein RS, Tuazon PT, Schalinske KL, Anderson SA, Traugh JA. 1993. Iron-responsive element-binding protein. Phosphorylation by protein kinase C. J Biol Cem 268:27363-27370. (Pubitemid 24006459)
2. Hamed MY. 1993. Binding of the ferric uptake regulation repressor protein (Fur) to Mn(II), Fe(II), Co(II), and Cu(II) ions as co-repressors: electronic absorption, equilibrium, and 57Fe Mossbauer studies. J Inorg Biochem 50:193-210. (Pubitemid 23129579)
3. Larson AA, Giovengo SL, Shi Q, Velazquez RA, Kovacs KJ. 2000. Zinc in the extracellular area of the central nervous system is necessary for the development of kainic acid-induced persistent hyperalgesia in mice. Pain 86:177-184. (Pubitemid 30211716)
4. McKee DJ, Frieden E. 1971. Binding of transition metal ions by ceruloplasmin (ferroxidase). Biochemistry 10:3880-3883.
5. Mecklenburg SL, Donohoe RJ, Olah GA. 1997. Tertiary structural changes and iron release from human serum transferrin. J Mol Bio 270:739-750. (Pubitemid 27332063)
6. Nguyen TH, Craig A, Raymond KN. 1993. Transferrin: the role of conformational changes in iron removal by chelators. J Am Chem Soc 115:6758-6764. (Pubitemid 23276373)
7. Sarkar B. 1987. Metal protein interactions. Progr Food Nutrition Sci 11:363-400.
8. Klausner RD, Rouault TA, Harford JB. 1993. Regulating the fate of mRNA: The control of cellular iron metabolism. Cell 72:19-28.
9. Leibold EA, Guo B. 1992. Iron-dependent regulation of ferritin and transferrin receptor expression by the iron-responsive element binding protein. Ann Rev Nutrition 12:345-368.
10. Theil EC. 1990. Regulation of ferritin and transferrin receptor mRNAs. J Biol Chem 265:4771-4774. (Pubitemid 20117103)
11. Hovorka SW, Hong J, Cleland JL, Schöneich C. 2001. Metal-catalyzed oxidation of human growth hormone: modulation by solvent-induced changes of protein conformation. J Pharm Sci 90:58-69. (Pubitemid 32050477)
12. Li S, Nguyen TH, Schöneich C, Borchardt RT. 1995. Aggregation and precipitation of human relaxin induced by metal-catalyzed oxidation. Biochemistry 34:5762-5772.
13. Stadtman ER. 1990. Metal ion-catalyzed oxidation of proteins: biochemical mechanism and biological consequences. Free Rad Biol Med 9:315-325.
14. Stadtman ER, Oliver CN. 1991. Metal-catalyzed oxidation of proteins. Physiological consequences. J Biol Chem 266:2005-2008.
15. Uversky VN, Li J, Fink AL. 2001. Metal-triggered structural transformations, aggregation, and fibrillation of human alpha-synuclein. A possible molecular NK between Parkinson's disease and heavy metal exposure. J Biol Chem 276:44284-44296. (Pubitemid 37384003)
16. Phan G, Le Gall B, Deverre JR, Fattal E, Benech H. 2006. Predicting plutonium decorporation efficacy after intravenous administration of DTPA formulations: Study of pharmacokinetic-pharmacodynamic relationships in rats. Pharm Res 23:2030-2035.
17. Porter JB, Gyparaki M, Burke LC, Huehns ER, Sarpong P, Saez V, Hider RC. 1988. Iron mobilization from hepatocyte monolayer cultures by chelators: the importance of membrane permeability and the iron-binding constant. Blood 72:1497-1503. (Pubitemid 18268625)
18. st ed. New York, NY: John Wiley & Sons Inc.
19. nd ed. London: The British Drug Houses, Ltd.
20. Andergee G, Arnaud-Neu F, Delgado R, Felcman J, Popov K. 2005. Critical evaluation of stability constants of metal complexes of complexones for bimedical and environmental applications. Pure Appl Chem 77:1445-1495. (Pubitemid 41296278)
21. FDA 2009. Questions and answers on Edetate Disodium (marketed as Endrate and generic products).
22. FDA 2008. Edetate Disodium (marketed as Endrate and generic products).
23. rd ed. New York: Informa HealthCare.
24. th ed. Chicago Pharmaceutical press. pp. 225-228.
25. th ed. Chicago Pharmaceutical press.
26. FDA 2008. Questions and answers on Edetate Disodium
27. [2008] Bayer withdraws liquid formulation of Leukine in US due to adverse reactions. Doctor's guide channels.
28. Anonymous, 2008 Bayer announces availability of reformulated liquid leukine®. Bayer Healthcare. http://pharma.bayer.com/scripts/pages/en/news- room/news-room55.php.
29. Li S, Schöneich C, Wilson GS, Borchardt RT. 1993. Chemical pathways of peptide degradation. V. Ascorbic acid promotes rather than inhibits the oxidation of methionine to methionine sulfoxide in small model peptides. Pharm Res 10:1572-1579.
30. Chaberek SA, Frost AE, Doran MA, Bicknell NJ. 1959. Interactions of some divalent metal ions with diethylenetriamine-pentaacetic acid. J Inorg Nucl Chem 11:184-196.
31. Vandegaer J, Chaberck SA, Frost AE. 1959. Iron chelates of diethylenetriaminepentaacetic acid. J Inorg Nucl Chem 11:210-221.
32. Skochdopole R, Schaberek S. 1959. Iron chelates of N- hydroxyethylethylenediaminetriacetic acid. J Inorg Nucl Chem 11:222-233.
33. Bhattacharyya MH, Breitenstein BD, Metivier H, Muggenburg B, Stradling GN, Volf V, editors. 1992. Guidebook for the treatment of accidental internal radionuclide contamination of workers. Ashford: Nuclear Technology Publishing.
34. Fisher DR. 2000. Decorporation: officially a word. Health Physics 78:563-565.
35. Norwood WD. 1962. Therapeutic removal of plutonium in humans. Health Physics 8:747-750.
36. Crisponi G, Remelli M. 2008. Iron chelating agents for the treatment of iron overload. Coordination Chemistry Reviews 252:1225-1240.
37. Faa G, Crisponi G. 1999. Iron chelating agents in clinical practice. Coordination Chemistry Reviews 184:291-310.
38. Srivastava RC, Dwivedi PP, Behari JR, Athar M. 1986. Evaluation of LD50 of some polyaminocarboxylic acids used as chelating drugs in metal intoxication. Toxicol Lett 32:37-40. (Pubitemid 16045772)
39. Durbin PW, Kullgren B, Xu J, Raymond KN. 1998. Development of decorporation agents for the actinides. Radiat Prot Dosimetry 79:433-443.
40. Crawley FE, Haines JW. 1979. The dosimetry of carbon-14 labeled compounds: the metabolism of diethylenetriamine pentaacetic acid (DTPA) in the rat. Intnl J Nucl Med Biol 6:9-15.
41. Stevens W, Bruenger FW, Atherton DR, Buster DS, Howerton G. 1978. The retention and distribution of 241Am and 65Zn, given as DTPA chelates in rats and of [14C]DTPA in rats and beagles. Radiation Res 75:397-409.
42. Stather JW, Smith H, Bailey MR, Birchall A, Bulman RA, Crawley FE. 1983. The retention of 14C-DTPA in human volunteers after inhalation or intravenous injection. Health Physics 44:45-52. (Pubitemid 13130449)
43. Pace CN, Vajdos F, Fee L, Grimsley G, Gray T. 1995. How to measure and predict the molar absorption coefficient of a protein. Prot Sci 4:2411-2423.
44. Marx G, Chevion M. 1986. Site-specific modification of albumin by free radicals. Reaction with copper(II) and ascorbate. Biochem J 236:397-400.
45. Uchida K, Kawakishi S. 1994. Identification of oxidized histidine generated at the active site of Cu, Zn-superoxide dismutase exposed to H2O2. Selective generation of 2-oxo-histidine at the histidine 118. J Biol Chem 269:2405-2410. (Pubitemid 24978481)
46. Kim K, Rhee SG, Stadtman ER. 1985. Nonenzymatic cleavage of proteins by reactive oxygen species generated by dithiothreitol and iron. J Biol Chem 260:15394-15397. (Pubitemid 16170066)
47. Cleland JL, Powell MF, Shire SJ. 1993. The development of stable protein formulations: a close look at protein aggregation, deamidation, and oxidation. Crit Revw Therap Drug Carrier Syst 10:307-377.
48. Manning MC, Patel K, Borchardt RT. 1989. Stability of protein pharmaceuticals. Pharm Res 6:903-918.
49. Chen T. 1992. Formulations concerns of protein drugs. Drug Dev Indust Pharm 18:1311-1354.
50. Shirley BA, editor. 1995. Protein stability and folding: Theory and practice. Totowa, New Jersey: Humana press Inc.
51. nd ed. New York. Springer
52. Derrick TS, Kashi RS, Durrani M, Jhingan A, Middaugh CR. 2004. Effect of metal cations on the conformation and inactivation of recombinant human factor VIII. J Pharm Sci 93:2549-2557.